Matinas BioPharma拟议交易:获400万美元预付款,潜在里程碑付款最高1750万美元及未来中个位数特许权使用费

美股速递
Jul 13

Matinas BioPharma Holdings, Inc. 披露了一项拟议交易,公司将获得400万美元的预付款,并可依据后续潜在里程碑的实现情况,额外获取最高达1750万美元的款项。此外,公司还有权获得未来销售额的中个位数百分比作为特许权使用费。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10